Regulation of endothelial barrier responses and permeability

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Citation (Scopus)

Abstract

The endothelial cell (EC) lining of the systemic and pulmonary vasculatures was considered for decades to exist merely as an inert and passive semipermeable cellular barrier between the blood and the interstitium of all tissues. During the early 1960s, however, Majno and Palade described the ultrastructural appearance of an actively contracted endothelium in pulmonary vessels previously exposed to the edemagenic agent histamine (1), thus igniting a controversy over whether the endothelium plays an active role in the inflammatory response. It is now well recognized that endothelial activities are critical and essential aspects of inflammation. Disruption of the integrity of the endothelial barrier results in marked increases in permeability to fluids leading to tissue edema and pain (dolor), and leukocyte infiltration into tissues (rubor and calor). When persistent and of significant intensity, this process invariably progresses to organ dysfunction. For example, in systemic inflammatory states such as sepsis, increased vascular permeability results in high morbidity and mortality via multiorgan dysfunction, including acute renal or hepatic failure, cardiac dysfunction, and respiratory insufficiency. Despite multiple attempts to improve upon the adverse clinical outcomes associated with increased endothelial permeability, the termination of fulminant edema with restoration of endothelial integrity remains an unrealized goal. Considerable progress in the past several years, however, suggests that several barrier-enhancing agents (or their selective derivatives with greater receptor selectivity) may be on the horizon for therapeutic purposes. It also should be noted that in selective vascular cells such as the cerebral circulation, the goal may be to actually increase permeability in order to increase the access of novel therapeutics across the blood–brain barrier (Figure 113.1).

Original languageEnglish (US)
Title of host publicationEndothelial Biomedicine
PublisherCambridge University Press
Pages1015-1029
Number of pages15
ISBN (Print)9780511546198, 0521853761, 9780521853767
DOIs
StatePublished - Jan 1 2007
Externally publishedYes

Fingerprint

Permeability
Tissue
Endothelium
Edema
Cerebrovascular Circulation
Histamine Agents
Nociceptive Pain
Lung
Acute Liver Failure
Endothelial cells
Capillary Permeability
Linings
Infiltration
Acute Kidney Injury
Respiratory Insufficiency
Restoration
Blood Vessels
Sepsis
Leukocytes
Blood

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Garcia, J. GN. (2007). Regulation of endothelial barrier responses and permeability. In Endothelial Biomedicine (pp. 1015-1029). Cambridge University Press. https://doi.org/10.1017/CBO9780511546198.114

Regulation of endothelial barrier responses and permeability. / Garcia, Joe GN.

Endothelial Biomedicine. Cambridge University Press, 2007. p. 1015-1029.

Research output: Chapter in Book/Report/Conference proceedingChapter

Garcia, JGN 2007, Regulation of endothelial barrier responses and permeability. in Endothelial Biomedicine. Cambridge University Press, pp. 1015-1029. https://doi.org/10.1017/CBO9780511546198.114
Garcia JGN. Regulation of endothelial barrier responses and permeability. In Endothelial Biomedicine. Cambridge University Press. 2007. p. 1015-1029 https://doi.org/10.1017/CBO9780511546198.114
Garcia, Joe GN. / Regulation of endothelial barrier responses and permeability. Endothelial Biomedicine. Cambridge University Press, 2007. pp. 1015-1029
@inbook{8cb62e148d6a4d42b8219fabc88b68c0,
title = "Regulation of endothelial barrier responses and permeability",
abstract = "The endothelial cell (EC) lining of the systemic and pulmonary vasculatures was considered for decades to exist merely as an inert and passive semipermeable cellular barrier between the blood and the interstitium of all tissues. During the early 1960s, however, Majno and Palade described the ultrastructural appearance of an actively contracted endothelium in pulmonary vessels previously exposed to the edemagenic agent histamine (1), thus igniting a controversy over whether the endothelium plays an active role in the inflammatory response. It is now well recognized that endothelial activities are critical and essential aspects of inflammation. Disruption of the integrity of the endothelial barrier results in marked increases in permeability to fluids leading to tissue edema and pain (dolor), and leukocyte infiltration into tissues (rubor and calor). When persistent and of significant intensity, this process invariably progresses to organ dysfunction. For example, in systemic inflammatory states such as sepsis, increased vascular permeability results in high morbidity and mortality via multiorgan dysfunction, including acute renal or hepatic failure, cardiac dysfunction, and respiratory insufficiency. Despite multiple attempts to improve upon the adverse clinical outcomes associated with increased endothelial permeability, the termination of fulminant edema with restoration of endothelial integrity remains an unrealized goal. Considerable progress in the past several years, however, suggests that several barrier-enhancing agents (or their selective derivatives with greater receptor selectivity) may be on the horizon for therapeutic purposes. It also should be noted that in selective vascular cells such as the cerebral circulation, the goal may be to actually increase permeability in order to increase the access of novel therapeutics across the blood–brain barrier (Figure 113.1).",
author = "Garcia, {Joe GN}",
year = "2007",
month = "1",
day = "1",
doi = "10.1017/CBO9780511546198.114",
language = "English (US)",
isbn = "9780511546198",
pages = "1015--1029",
booktitle = "Endothelial Biomedicine",
publisher = "Cambridge University Press",

}

TY - CHAP

T1 - Regulation of endothelial barrier responses and permeability

AU - Garcia, Joe GN

PY - 2007/1/1

Y1 - 2007/1/1

N2 - The endothelial cell (EC) lining of the systemic and pulmonary vasculatures was considered for decades to exist merely as an inert and passive semipermeable cellular barrier between the blood and the interstitium of all tissues. During the early 1960s, however, Majno and Palade described the ultrastructural appearance of an actively contracted endothelium in pulmonary vessels previously exposed to the edemagenic agent histamine (1), thus igniting a controversy over whether the endothelium plays an active role in the inflammatory response. It is now well recognized that endothelial activities are critical and essential aspects of inflammation. Disruption of the integrity of the endothelial barrier results in marked increases in permeability to fluids leading to tissue edema and pain (dolor), and leukocyte infiltration into tissues (rubor and calor). When persistent and of significant intensity, this process invariably progresses to organ dysfunction. For example, in systemic inflammatory states such as sepsis, increased vascular permeability results in high morbidity and mortality via multiorgan dysfunction, including acute renal or hepatic failure, cardiac dysfunction, and respiratory insufficiency. Despite multiple attempts to improve upon the adverse clinical outcomes associated with increased endothelial permeability, the termination of fulminant edema with restoration of endothelial integrity remains an unrealized goal. Considerable progress in the past several years, however, suggests that several barrier-enhancing agents (or their selective derivatives with greater receptor selectivity) may be on the horizon for therapeutic purposes. It also should be noted that in selective vascular cells such as the cerebral circulation, the goal may be to actually increase permeability in order to increase the access of novel therapeutics across the blood–brain barrier (Figure 113.1).

AB - The endothelial cell (EC) lining of the systemic and pulmonary vasculatures was considered for decades to exist merely as an inert and passive semipermeable cellular barrier between the blood and the interstitium of all tissues. During the early 1960s, however, Majno and Palade described the ultrastructural appearance of an actively contracted endothelium in pulmonary vessels previously exposed to the edemagenic agent histamine (1), thus igniting a controversy over whether the endothelium plays an active role in the inflammatory response. It is now well recognized that endothelial activities are critical and essential aspects of inflammation. Disruption of the integrity of the endothelial barrier results in marked increases in permeability to fluids leading to tissue edema and pain (dolor), and leukocyte infiltration into tissues (rubor and calor). When persistent and of significant intensity, this process invariably progresses to organ dysfunction. For example, in systemic inflammatory states such as sepsis, increased vascular permeability results in high morbidity and mortality via multiorgan dysfunction, including acute renal or hepatic failure, cardiac dysfunction, and respiratory insufficiency. Despite multiple attempts to improve upon the adverse clinical outcomes associated with increased endothelial permeability, the termination of fulminant edema with restoration of endothelial integrity remains an unrealized goal. Considerable progress in the past several years, however, suggests that several barrier-enhancing agents (or their selective derivatives with greater receptor selectivity) may be on the horizon for therapeutic purposes. It also should be noted that in selective vascular cells such as the cerebral circulation, the goal may be to actually increase permeability in order to increase the access of novel therapeutics across the blood–brain barrier (Figure 113.1).

UR - http://www.scopus.com/inward/record.url?scp=64549086858&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=64549086858&partnerID=8YFLogxK

U2 - 10.1017/CBO9780511546198.114

DO - 10.1017/CBO9780511546198.114

M3 - Chapter

AN - SCOPUS:64549086858

SN - 9780511546198

SN - 0521853761

SN - 9780521853767

SP - 1015

EP - 1029

BT - Endothelial Biomedicine

PB - Cambridge University Press

ER -